论文部分内容阅读
慢性髓细胞性白血病(CML)是一种恶性克隆的骨髓增殖性疾病,其特征性标志是9号和22号染色体之间的异位t(9;22)形成的Ph染色体,从而形成BCR-ABL融合基因,这导致细胞的增殖不受控制和凋亡减少,与CML细胞的恶性行为有明显的关系。BCR-ABL融合基因是CML的致病基因,酪氨酸激酶抑制剂(TKIs)作为CML的靶向药
Chronic myelogenous leukemia (CML) is a malignant clonal myeloproliferative disease characterized by a Ph chromosome formed by the ectopic t (9; 22) between chromosomes 9 and 22, forming the BCR- ABL fusion gene, which leads to uncontrolled cell proliferation and decreased apoptosis, and has a clear relationship with the malignant behavior of CML cells. The BCR-ABL fusion gene is a causative gene of CML, and tyrosine kinase inhibitors (TKIs) are targeted drugs for CML